source
- Regulators urge risk-based lifecycle approach for AI tools amid election-linked FDA uncertaintyA panel of regulatory experts at the RAPS AI in Regulatory Conference in Barcelona urged professionals using AI tools to adopt a risk-based, life-cycle perspective rather than focusing solely on va…
- Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked NovemberAlso lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.